Compare MEC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | RLMD |
|---|---|---|
| Founded | 1945 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.4M | 524.9M |
| IPO Year | 2019 | 2012 |
| Metric | MEC | RLMD |
|---|---|---|
| Price | $26.55 | $5.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $24.33 | $12.40 |
| AVG Volume (30 Days) | 501.1K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $12.10 | $0.55 |
| 52 Week High | $38.76 | $8.00 |
| Indicator | MEC | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 35.69 |
| Support Level | $16.56 | $4.85 |
| Resistance Level | $28.00 | $7.28 |
| Average True Range (ATR) | 2.15 | 0.39 |
| MACD | -0.70 | 0.01 |
| Stochastic Oscillator | 9.85 | 19.50 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.